The Polycystic Kidney Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Polycystic Kidney Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued products.
GlobalData tracks 56 drugs in development for Polycystic Kidney Disease by 47 companies/universities/institutes. The top development phase for Polycystic Kidney Disease is preclinical with 24 drugs in that stage. The Polycystic Kidney Disease pipeline has 51 drugs in development by companies and five by universities/ institutes. Some of the companies in the Polycystic Kidney Disease pipeline products market are: Chinook Therapeutics, Goldfinch Bio and Healx.
The key targets in the Polycystic Kidney Disease pipeline products market include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31), Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC 5.6.1.6), and Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98).
The key mechanisms of action in the Polycystic Kidney Disease pipeline product include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31) Activator with five drugs in Preclinical. The Polycystic Kidney Disease pipeline products include eight routes of administration with the top ROA being Oral and eight key molecule types in the Polycystic Kidney Disease pipeline products market including Small Molecule, and Monoclonal Antibody.
Polycystic Kidney Disease overview
Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. PKD symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination, and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.
For a complete picture of Polycystic Kidney Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
